1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
Small Molecule Approaches for Rapid and Robust Treatment (SMART) Prize is sponsored by Biomedical Advanced Research and Development Authority (BARDA), Administration for Strategic Preparedness and Response (ASPR). The SMART Prize is a $100 million competition to develop broad-spectrum, small-molecule antiviral therapies targeting viruses in the Togaviridae and Flaviviridae families (e.g., dengue, Zika, West Nile, chikungunya).
It aims to unite experts in drug development, virology, artificial intelligence, medicinal chemistry, and public health to create accessible and resilient antiviral drugs. The first stage focuses on concept papers for discovering or advancing broad-spectrum antivirals.
Get alerted about grants like this
Save a search for “Biomedical Advanced Research and Development Authority (BARDA), Administration for Strategic Preparedness and Response (ASPR)” or related topics and get emailed when new opportunities appear.
Search similar grants →According to the current listing, eligibility includes: Experts in drug development, virology, artificial intelligence, medicinal chemistry, and public health. Small businesses with relevant expertise would be eligible to participate. Confirm the full requirements in the official notice before applying.
The current listing shows $100,000,000 total prize pool. Verify award ceilings, matching requirements, and allowable costs in the official notice.
Small Molecule Approaches for Rapid and Robust Treatment (SMART) Prize is funded by Biomedical Advanced Research and Development Authority (BARDA), Administration for Strategic Preparedness and Response (ASPR). Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
Past winners and funding trends for this program
The NSF FY 2026-2030 Strategic Plan reorganizes the agency around three goals, names AI, quantum, and biotech as the critical technologies, codifies Gold Standard Science, and explicitly targets applicant burden. The implications for proposal strategy are bigger than they look.
Read articleOn May 31, NSF announced the restart of its SBIR and STTR programs with a \$250 million FY26 allocation, a Project Pitch portal reopening June 2, a first full-proposal deadline of July 27, 2026, and additional windows on November 4 and March 4, 2027. Phase I tops out at \$305K, Phase II at \$1.25M, and a new Strategic Breakthrough lane extends invited Phase II companies up to \$30M. A separate \$40M instrumentation pilot (NSF 26-511) funds next-generation scientific tools. Here is what changed from prior cycles, who the program actually fits, and how to position a Project Pitch for the July deadline.
Read articlePublic Law 119-83 was signed April 13, 2026, reauthorizing SBIR/STTR through 2031. The Department of War issued its implementation announcement April 20 and released over 90 topics in six weeks. The new Accelerated Research for Transition (ART) Program restructures Phase II-to-acquisition transition, Strategic Breakthrough Awards offer $30M per project with 100% matching, and CMMC Level 2 self-assessment has been the compliance floor since November 10, 2025. Here is how to read the post-reauthorization DoW pipeline.
Read article